ArticleBMC public health2023
Trends in cause of death among patients with renal cell carcinoma in the United States: a SEER-based study.
Article in BMC public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 23 citations in OpenAlex.
- Incidence and impact of pseudoprogression and mixed responses in metastatic renal cell carcinoma patients treated with ipilimumab/nivolumab: a retrospective analysis.Acta oncologica (Stockholm, Sweden) · 2026Article
- A non-complement role for C1R rewires integrin and death-receptor signaling to drive renal cancer metastasis.Molecular cancer · 2026Article
- Brain metastases from renal cell carcinoma: a large retrospective claims-based oncology cohort analysis of prevalence, chronicity, and survival outcomes.Journal of neuro-oncology · 2025Article
- TET1 methylation and mRNA expression in renal cell carcinoma: implications for tumor staging and prognosis.European journal of medical research · 2025Article
- Longitudinal Patterns of Cardiovascular Disease and Cancer Mortality in Renal Cell Carcinoma Patients by Tumor Stage.JACC. CardioOncology · 2025Article
- piRNAs and circRNAs acting as diagnostic biomarkers in clear cell renal cell carcinoma.Scientific reports · 2025Article
- Prognosis impact and clinical findings in renal cancer patients: comparative analysis between public and private health coverage in a cross-sectional and multicenter context.Cancer causes & control : CCC · 2025Article
- Cardiovascular Disease and Other Competing Causes of Death in Older Kidney Cancer Patients.Reviews in cardiovascular medicine · 2025Article
- Niemann-Pick C1-like 1 as a Prognostic Marker in Renal Cell Carcinoma: A Retrospective Cohort Study.Life (Basel, Switzerland) · 2024Article
- Longitudinal Trends of Comorbidities and Survival Among Kidney Cancer Patients in Asian Population.Cancer medicine · 2024Article
- Article
- Integrating tumor and healthy epithelium in a micro-physiology multi-compartment approach to study renal cell carcinoma pathophysiology.Scientific reports · 2024Article
- Potential Nephroprotective Effect of Kaempferol: Biosynthesis, Mechanisms of Action, and Clinical Prospects.Advances in pharmacological and pharmaceutical sciences · 2024Review
- Increased risk of cardiovascular disease among kidney cancer survivors: a nationwide population-based cohort study.Frontiers in oncology · 2024Article
- The Metastasis Pattern of Renal Cell Carcinoma Is Influenced by Histologic Subtype, Grade, and Sarcomatoid Differentiation.Medicina (Kaunas, Lithuania) · 2023Article
- Second-Line Treatment of Metastatic Renal Cell Carcinoma in the Era of Predictive Biomarkers.Diagnostics (Basel, Switzerland) · 2023Article
- Second malignant tumors and non-tumor causes of death for patients with localized and regional kidney cancer after diagnosis.European journal of medical research · 2023Article
- Outcomes of acute myocardial infarction in patients with renal cell carcinoma: a propensity-matched analysis from the national inpatient sample.Archives of medical sciences. Atherosclerotic diseases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRenal cell carcinoma (RCC) survival has improved due to recent developments in RCC treatment. Therefore, other co-morbid conditions may have a more critical role. This study aims to explore the common causes of death in patients with RCC to improve the management and survival of RCC.
methodWe used the Surveillance, Epidemiology, and End Results (SEER) (1992-2018) database to get patients with RCC. We calculated the percentage of total deaths of six kinds of the cause of death (COD) and the cumulative incidence of death for each selected cause over survival time. The joinpoint regression was utilized to present the trend of mortality rate by COD.
resultsWe enrolled 107,683 cases with RCC. RCC was the leading cause of death in patients with RCC [25376(48.3%)], followed by cardiovascular diseases [9023(17.2%)], other cancers [8003 (15.2%)], other non-cancer diseases [4195 (8%)], non-disease cause [4023 (7.7%)], and respiratory diseases [1934 (3.6%)]. The proportion of patients who died of RCC decreased gradually over survival time, and this value decreased from 69.71% in 1992-1996 to 38.96% in 2012-2018. The non-RCC cause mortality rate showed an increasing trend, whereas a slight decrease was observed in RCC specific mortality rate. The distribution of such conditions varied across different patient populations.
conclusionRCC was still the primary COD of patients with RCC. However, non-RCC cause death was increasingly important among RCC patients in recent two decades. Cardiovascular disease and other cancers were crucial co-morbidities that required significant attention in the management of RCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.